ClinicalTrials.gg
RecruitingNCT06117878Updated Nov 7, 2023

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

An Early Phase 1 interventional study of NK510 and NK510 in Osteosarcoma and Soft Tissue Sarcoma, sponsored by Base Therapeutics (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 10 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Base Therapeutics (Shanghai) Co., Ltd. · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Sep 2022, registered Oct 2023).
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
10 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Osteosarcoma with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Osteosarcoma · China.

Planned enrollment
38th of 42
12 · median 44
Started
2022
with 1 other
Phase 1
10 of 60
7 open now
Primary completion
2024-09
later than 3 of 25 live
Registered
39th of 60
by date
Lead sponsor
1 of 60
Base Therapeutics (Shanghai) Co., Ltd.

Among the 60 studies in Osteosarcoma with a site in China, this one is the 38th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 in phase 1, reaches primary completion later than 3 of the 25 other live ones, and was the 39th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

22 of the 60 studies in Osteosarcoma with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 10 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Osteosarcoma with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

03

Conditions studied

  • Osteosarcoma
  • Soft Tissue Sarcoma
04

Who can participate

Ages eligible
10 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed obtained,can be followed upon protocol;
  • age ≥ 10 years;
  • histopathologically confirmed diagnosis of advanced osteosarcoma or non-specific soft tissue sarcoma;
  • Subjects for dose-escalation studies: failed to at least one chemotherapy regimen and undergoing disease progression or untolerable drug toxicity before enrollment;Subjects for postoperative therapy study: radical surgery within 3 months before the first infusion of NK510 and no local recurrence or distant metastasis;
  • according to 1.1,Recurrent and patients have at least one at baseline. Patients receiving adjuvant treatment after radical surgery have no measurable lesions on imaging examination;
  • physical status score of 0 or 1;
  • Expected survival >=12 weeks;
  • Female subjects of childbearing age or male subjects whose sexual partners are female subjects of childbearing age are required to take effective measures throughout the entire treatment period and 6 months after the treatment period;
  • good organ and bone marrow hematopoietic function, the laboratory test values within 7 days before enrollment meet the following requirements (no medication for blood components, cell growth factors, or albumin correction treatment is allowed within the first 14 days of obtaining laboratory test), as follows:

    1. Hematological: ≥1.5×10\^9/L; count ≥ 75×10\^9/L; ≥ 9 g/dL;
    2. Hepatic:Total ≤1.5 x ; and AST≤2.5×ULN;Albumin ≥ 28 g/L; Alkaline phosphatase ≤ 5 × ULN;
    3. Renal:Serum creatinine ≤ 1.25 × ULN or ≥ 50mL/min (Cockcroft Fault formula);Patients whose urine routine results show urinary protein\<2+or whose baseline urine routine test shows urinary protein ≥ 2+will undergo 24-hour urine collection with a 24-hour urine protein quantification of\<1g.
    4. Coagulation:International standardized ratio () ≤ 2, and activated partial thromboplastin time ≤ 1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

  • Have received local or systemic anti-tumor treatment within 4 weeks before the first administration of NK510(Chinese medicine or traditional Chinese patent medicines and simple preparations is 2 weeks before administration);
  • Untreated active (HbsAg positive and peripheral blood HBV-DNA>1000 IU/ml); virus antibody positive;
  • Patients with central nervous system ;
  • Previous history of arterial and venous thromboembolism events, including myocardial infarction, unstable angina, cerebrovascular accident or , pulmonary embolism, deep vein thrombosis, or any other serious thromboembolism within 6 month before NK510 first infusion;
  • Severe bleeding tendency or coagulation dysfunction, or undergoing thrombolytic therapy;
  • Uncontrolled hypertension, with systolic blood pressure ≥ 150mmHg or diastolic blood pressure ≥ 100mmHg after optimal medical treatment, hypertension crisis or history of hypertensive encephalopathy;
  • Symptomatic congestive heart failure ( classification II-IV). Symptomatic or poorly controlled arrhythmia. The is prolonged, with QTc>450ms for males and 470ms for females. The echocardiography shows that the at rest is less than 50%;
  • Active pulmonary tuberculosis (TB), who is receiving anti-tuberculosis treatment or has received anti-tuberculosis treatment within one year before the first study medication;
  • People infected with (HIV), known as active syphilis carriers;
  • Severe infections that are active or poorly controlled clinically. Severe infection within 4 weeks prior to initial administration, including but not limited to hospitalization due to complications such as infection, bacteremia, or severe pneumonia;
  • Administer therapeutic antibiotics orally or intravenously within one week before starting the study treatment;
  • Active diseases requiring systemic treatment have occurred within 2 years prior to the first administration. Allow the use of alternative therapies (such as thyroxine, insulin, or physiological for adrenal or pituitary insufficiency). A known history of primary immunodeficiency;
  • Within 4 weeks before the first administration, drugs have been used, excluding local corticosteroids administered through nasal spray, inhalation, or other means, or systemic corticosteroids administered in physiological doses (i.e. no more than 10 mg/day of prednisone equivalent dose). Temporary use of corticosteroids is allowed for the prevention of allergic reactions or the treatment of respiratory distress symptoms such as asthma and ;
  • Within 4 weeks before the first administration or planned to receive during the study period;
  • Uncontrolled/uncorrectable metabolic disorders or other non malignant tumor organ diseases or systemic diseases or secondary reactions to cancer, which can lead to high medical risk and/or uncertainty in survival evaluation;
  • Other acute or chronic diseases, mental illnesses, or abnormal laboratory test values that may lead to increased risk of study participation or drug administration, or interference with the interpretation of study results, based on the judgment of the investigator, the patient is not eligible to participate in this study;
  • Diagnosed as other malignant tumors within 5 years prior to the first administration, excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ after radical resection;
  • Those who have participated in clinical trials of other drugs and received treatment with drugs within 4 weeks before the first administration;
  • Within 2 weeks before the first administration, medication with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control pleural or ascites) has been received;
  • Pregnant or lactating female patients.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Group A(low-dose group)

    NK510 1×10\^9 NK cells/dose.

    Drug: NK510

  • Experimental
    Group B(medium-dose group)

    NK510 3×10\^9 NK cells/dose.

    Drug: NK510

  • Experimental
    Group C(high-dose group)

    NK510 9×10\^9 NK cells/dose.

    Drug: NK510

  • Experimental
    Group D(high-dose group,postoperative adjuvant treatmen)

    NK510 9×10\^9 NK cells/dose.

    Drug: NK510

Interventions

  • DrugNK510

    NK510 will be administered through intravenous infusion.once a week,for a total of six times.

  • DrugNK510

    NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity

    To evaluate the DLT during N510 treatment

    Time frame: 6 weeks

  2. Maximal Tolerable Dose

    To evaluate the MTD of NK510

    Time frame: 6 weeks

Secondary outcomes

  1. Overall response rate (ORR)

    Effectiveness Metrics

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Sep 2024, 24 months after the start.

Of 49 phase 1 interventional studies under Osteosarcoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 134. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 7, 2023
StartActual
Sep 1, 2022
Primary completionEst.
Sep 1, 2024
CompletionEst.
Sep 1, 2024
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06117878
Lead sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Sep 1, 2022
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Nov 7, 2023

Study contacts

Jun Yan, PhD
Contact
yanjun@basetherapeutics.com
+8618621668515
Yingqi Hua, PhD
Contact
hua_yingqi@163.com
+86 138 1765 1474
Yingqi Hua, phD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Base Edited Natural Killer Cells NK510

Start the discussion